Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Johns Hopkins, Baltimore, Maryland, United States

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

University of Texas Southwestern, Dallas, Texas, United States

START Dallas Fort Worth, Fort Worth, Texas, United States